Pfizer Expands Pneumococcal Vaccine Push With New Programs

Pfizer reported positive Phase 2 data for its 25-valent pneumococcal conjugate vaccine candidate (25vPnC), showing 8.8 to 15 times higher immune responses against serotype 3 compared to PREVNAR 20. The company is advancing to a pivotal Phase 3 pediatric program with up to 2,400 participants and plans to develop a 35-valent adult vaccine candidate entering clinical development by end of 2026.

05/20/2026, 9:14 AM • Benzinga

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Vaxcyte announced publication of positive Phase 1/2 clinical trial results for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in The Lancet Infectious Diseases. The vaccine demonstrated robust immune responses across all 31 serotypes and a safety profile similar to Prevnar 20. Based on these results, VAX-31 has advanced into Phase 3 clinical trials (OPUS program) with topline data expected in Q4 2026. VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease in U.S. adults aged 50 and older.

03/18/2026, 7:34 PM • GlobeNewswire

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of common stock at $50 per share, including the full exercise of underwriters' option for 1,650,000 additional shares. The funds will support the company's clinical-stage vaccine development programs.

02/02/2026, 4:05 PM • Benzinga

Vaxcyte Announces Pricing of $550 Million Public Offering

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, announced the pricing of an underwritten public offering of 11 million shares at $50 per share, generating $550 million in gross proceeds. The offering is expected to close on February 2, 2026. The company is developing VAX-31, a 31-valent pneumococcal conjugate vaccine candidate in Phase 3 adult and Phase 2 infant clinical programs, along with other vaccine candidates in its pipeline.

01/29/2026, 11:33 PM • GlobeNewswire

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte announced progress on VAX-31, its 31-valent pneumococcal conjugate vaccine, with first participants dosed in the OPUS-2 Phase 3 adult trial evaluating concomitant administration with seasonal influenza vaccine. The company plans to initiate OPUS-3 Phase 3 trial in Q1 2026 for previously vaccinated adults and expects topline data from OPUS-1 in Q4 2026 and OPUS-2/OPUS-3 in H1 2027. For the infant indication, enrollment of 905 participants in the Phase 2 dose-finding study is complete, with data expected by end of H1 2027. Vaxcyte is also establishing manufacturing presence in North Carolina with a planned $1 billion commitment.

01/22/2026, 5:00 PM • GlobeNewswire

Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown

Thermo Fisher Scientific is issuing a four-part bond offering in the U.S. investment-grade market, with proceeds intended for general corporate purposes amid potential government shutdown concerns.

09/30/2025, 11:42 AM • Benzinga

Pneumococcal Infections Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight

The pneumococcal infection market is expected to grow steadily, driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives. Over 15 companies are developing 20+ pipeline therapies, with next-generation vaccines targeting broader serotype coverage.

08/21/2025, 1:00 PM • GlobeNewswire

Vaxcyte (PCVX) Q2 Loss Widens 11%

Vaxcyte reported a wider Q2 2025 net loss of $1.22 per share, driven by increased R&D and G&A expenses. The company advanced its VAX-31 vaccine program with FDA Breakthrough Therapy Designation and has $2.8 billion in cash to fund operations through mid-2028.

08/06/2025, 8:19 PM • The Motley Fool